The Diltiazem market is projected to reach US$ 832.52 million by 2028 from US$ 369.95 million in 2021; it is expected to grow at a CAGR of 12.3% from 2021 to 2028.
Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
Heart diseases are mostly observed in elderly people due to their weak immunity and major other health problems. The general aging factors lead to stiffening the heart and blood vessels that lead to heart disorders. As the age grows, the systolic blood pressure also rises, and it can cause cardiovascular disease. Thus, high blood pressure is a common cause of heart conditions in people aged 75 years and above. Coronary artery disease and heart failure are the next caused conditions. Although the incidence of arrhythmias is encompassing people of all age groups, its incidence is rising significantly among elderly people.
According to the Global Ageing 2019 survey, the world's population of people aged 65 and above totaled 703 million in 2019. The elderly demographic is expected to double to 1.5 billion people by 2050. The frequency of one person aged 65 and above is likely to increase from 1 in every 11 inhabitants in 2019 to 1 in every six inhabitants by 2025. This demographic is more susceptible to CVDs, such as arrhythmias. Similarly, according to the WHO, the percentage of people aged 60 years and above is estimated to reach 22% by 2050 from 12% in 2015. According to the report "Older Americans 2016: Key Indicators of Well-Being" by the Federal Interagency Forum on Aging-Related Statistics, 35.8% of individuals with age 85 and above had a mild or extreme cognitive disorder. Moreover, according to the United Nation's World Population Ageing 2017 report, in 2017, there were 962 million people across the world who were aged 60 years and above, and the number is expected to reach nearly 2.1 billion by 2050.
According to the US Census Bureau, the number of Americans aged 65 and above is expected to more than double from 46 million in 2016 to more than 98 million by 2060, with the 65-and-plus age group accounting for roughly 24% of the global population, up from 15% in 2016. In 2017, the European Union had the highest proportion of people aged 60 and above (25%). Other regions across the world are also experiencing a rising aging population, and by 2050, all regions of the world except Africa will have roughly a quarter or more of their inhabitants aged 60 and above. The number of elder people in the world is anticipated to reach US$ 1.4 billion by 2030 and US$ 2.1 billion by 2050 and will rise above US$ 3.1 billion by 2100. The elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population in the world leads to an increase in the incidence of cardiovascular disease, which bolsters the growth of the diltiazem market
Lucrative Regions for Diltiazem Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Market Insights
Increase in Cardiovascular Disease Incidence
Diltiazem is a calcium channel blocker. It lowers the heart rate and works by relaxing blood vessels in the body and heart. Blood flows more easily, and the heart works less hard to pump blood. Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility, also representing a good alternative for the treatment of stable chronic angina. Diltiazem has powerful cardiovascular effects caused by its actions on vascular smooth muscle, ventricular myocardium, and specialized conducting tissue. In individuals with normal ventricular function, it induces coronary and peripheral vasodilation, has a negative chronotropic and dromotropic impact, and has little to no negative inotropic effect. Diltiazem has potential use in a wide variety of cardiovascular disorders. It is extremely effective in relieving the coronary artery spasm associated with variant angina. When compared with nitrates in patients with exertional angina, diltiazem has similar efficacy.
According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death across the world. CVDs are a major cause of morbidity and affect more people than any other disease. A few CVDs are cerebrovascular disease, coronary heart disease, and rheumatic heart disease. Tobacco consumption, unhealthy diet, and physical inactivity are among major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels.
Atrial fibrillation (AFib) is the most common type of heart disorder, where the heart beats too fast, too slow, or in an irregular way. The Centers for Disease Control and Prevention (CDC) estimated that between 2.7 million and 6.1 million people are suffering from AFib in the US. In 2017, around 166,793 death certificates mention AFib and was the main cause deaths in 26,077 deaths. Every year over 454,000 hospitalizations and about 158,000 deaths are reported due to AFib in the US.
Furthermore, the European Society of Cardiology reported that Atrial fibrillation is the most common arrhythmia and accounts for 0.28% to 2.6% of healthcare spending in European countries. It also mentioned that patients suffering from atrial fibrillation have a five times higher risk of getting a stroke. From 20% to 30% of total strokes in Europe are caused due to atrial fibrillation. As per the study conducted by the European Society of Cardiology in 2016, ~7.6 million people aged 65 and more in the EU had atrial fibrillation. The European Society of Cardiology estimated that the number is expected to increase by 89% by 2060 and ~14.4 million people will have atrial fibrillation. Also, the prevalence of 7.8% is expected to reach 9.5% in 2060.
Furthermore, the prevalence of atrial fibrillation in Asia Pacific is also increasing. As per the report “BEYOND THE BURDEN: THE IMPACT OF ATRIAL FIBRILLATION IN ASIA PACIFIC” by Biosense Webster, published in 2019, more than 16 million people in Asia Pacific suffer from Atrial Fibrillation AF, which is affecting the middle-aged and the elderly population. The report also estimated that the number will reach about 72 million by 2050.
Prevalence of Atrial Fibrillation in APAC (by Country)
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Isoptin) are effective for initial ventricular rate control in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower. Furthermore, diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the growth of the diltiazem market.
Product Type-Based Insights
Based on product type, the market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market, whereas the capsules segment is expected to witness the fastest CAGR during 2021 to 2028.
Diltiazem Market, by Product Type – 2021 and 2028
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Application -Based Insights
Based on application, the market is segmented into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market, whereas the angina segment is expected to grow at the fastest CAGR during the coming years.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Diltiazem Market: Strategic Insights
Market Size Value in US$ 369.95 Million in 2021 Market Size Value by US$ 832.51 Million by 2028 Growth rate CAGR of 12.3% from 2021-2028 Forecast Period 2021-2028 Base Year 2021
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Diltiazem Market: Strategic Insights
| Market Size Value in | US$ 369.95 Million in 2021 |
| Market Size Value by | US$ 832.51 Million by 2028 |
| Growth rate | CAGR of 12.3% from 2021-2028 |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Companies operating in the diltiazem market emphasize on adopting the product innovations strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.
Diltiazem Market – Segmentation
By Product Type
- Tablet
- Capsules
- Injection
By Application
- Hypertension
- Angina
- Others
Diltiazem Market– by Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Bausch Health
- Teva Pharmaceutical Industries Ltd
- Mylan N.V
- Athenex
- Pfizer, Inc,
- Glenmark
- Sandoz (Novartis Ag)
- Sun Pharmaceutical Company Ltd
- Hikma Pharmaceuticals
- Zydus Pharmaceuticals
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product Type ; Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. 12 At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.
The factors that are driving and restraining factors that will affect Diltiazem market in the coming years. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
The Diltiazem market majorly consists of the players such as Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag),Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, Zydus Pharmaceuticals among others amongst others.
The US is the largest market for Diltiazem at a global level., In the United States hypertension was a primary or contributing factor in roughly half a million deaths in in recent years. Hypertension-related deaths have increased by 72 percent and 20 percent in rural and urban areas of the United States, respectively. According to Centers for Disease Control and Prevention, high blood pressure costs the United States about $131 billion each year. In the United States, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. According to the WHO in the United States, one person dies from cardiovascular disease every 36 seconds. Every year, over 655,000 Americans die from heart disease, accounting for one out of every four deaths.
The global diltiazem market based on product is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market, by product type. However , the capsules segment of Diltiazem Market is also expected to witness fastest CAGR of 12.8% during 2021 to 2028. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
Asia Pacific is expected to be the fastest-growing region and is likely to expand at a high growth rate due to government initiatives in drug approval process. Moreover, the rise in prevalence of cardiovascular disease such as angina, hypertension and arrythmia is likely to boost the growth of market in Asia-Pacific region. For instance, The rise in the cardiovascular diseases is observed due to the rise in the risk factors such as smoking, blood pressure, cholesterol and diabetes. The percentage of men who smoke in Japan is approximately 35.4% which is nearly double than the rate of smoking in US. The average blood pressure in Japan is nearly 130.5 and the cholesterol leverage averages approximately 201 mg/dl (5.2 mmol/L). However, the rate of diabetes is little less, compared to the rate in US. The rate of diabetes in Japan is approximately 7.2%. Owing to these factors the country is likely to demand more of the cardiovascular diagnostic and treatment devices in future.
The List of Companies - Diltiazem Market
- Bausch Health
- Teva Pharmaceutical Industries Ltd
- Mylan N.V
- Athenex
- Pfizer, Inc
- Glenmark
- Sandoz (Novartis Ag)
- Sun Pharmaceutical Company Ltd
- Hikma Pharmaceuticals
- Zydus Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Diltiazem Market
Aug 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Aug 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Aug 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)